Kamada (NASDAQ:KMDA) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA – Get Rating) in a report issued on Thursday morning. The firm issued a buy rating on the biotechnology company’s stock.

Kamada Stock Performance

Shares of KMDA stock traded down $0.15 on Thursday, reaching $4.23. The stock had a trading volume of 36,263 shares, compared to its average volume of 21,945. The stock has a market cap of $189.59 million, a P/E ratio of -84.58 and a beta of 1.00. Kamada has a 1 year low of $3.72 and a 1 year high of $5.94. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.90 and a current ratio of 1.84. The company has a 50 day simple moving average of $4.52 and a 200 day simple moving average of $4.49.

Hedge Funds Weigh In On Kamada

Institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP bought a new position in Kamada in the 4th quarter worth $41,000. Group One Trading L.P. raised its holdings in Kamada by 103.7% in the 1st quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 307,831 shares during the period. Y.D. More Investments Ltd bought a new position in Kamada in the 4th quarter worth $91,000. Calton & Associates Inc. raised its holdings in Kamada by 37.5% in the 4th quarter. Calton & Associates Inc. now owns 24,255 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 6,616 shares during the period. Finally, Metis Global Partners LLC raised its holdings in Kamada by 19.2% in the 4th quarter. Metis Global Partners LLC now owns 33,001 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 5,323 shares during the period. 15.29% of the stock is owned by institutional investors.

About Kamada

(Get Rating)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.